TuisNONOF • OTCMKTS
add
Novo Nordisk A/S
Vorige sluiting
$102,84
Dagwisseling
$101,70 - $106,19
Jaarwisseling
$94,36 - $149,55
Markkapitalisasie
354,10 mjd USD
Gemiddelde volume
34,33 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
CPH
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(DKK) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 71,31 mjd | 21,42% |
Bedryfskoste | 26,18 mjd | 18,44% |
Netto inkomste | 27,30 mjd | 21,46% |
Netto winsgrens | 38,28 | 0,03% |
Wins per aandeel | 6,12 | 22,40% |
EBITDA | 35,97 mjd | 22,20% |
Effektiewe belastingkoers | 20,60% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(DKK) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 74,88 mjd | 57,33% |
Totale bates | 397,44 mjd | 32,44% |
Totale aanspreeklikheid | 276,92 mjd | 33,71% |
Totale ekwiteit | 120,52 mjd | — |
Uitstaande aandele | 4,45 mjd | — |
Prys om te bespreek | 3,80 | — |
Opbrengs op bates | 22,05% | — |
Opbrengs op kapitaal | 48,72% | — |
Kontantvloei
Netto kontantverandering
(DKK) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 27,30 mjd | 21,46% |
Kontant van bedrywe | 43,85 mjd | 7,04% |
Kontant van beleggings | -20,90 mjd | -57,85% |
Kontant van finansiering | -18,40 mjd | 7,22% |
Netto kontantverandering | 4,20 mjd | -49,49% |
Beskikbare kontantvloei | 25,22 mjd | -14,56% |
Meer oor
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Its main product is the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt, denoted by the hieroglyph 𓃒. Wikipedia
Gestig
21 Des. 1923
Hoofkwartier
Webwerf
Werknemers
71 880